Markman Advisors
Patent Valuation, Monetization and Investments

Blog

Markman Advisors Patent Blog

by Zachary Silbersher

Posts tagged patent misuse
Is Corcept’s new Korlym lawsuit a game-changer against Teva?

Corcept Therapeutics ($CORT) recently filed a new lawsuit against Teva ($TEVA) related to Teva’s proposed generic for Korlym®.  The new suit asserts three new patents that were recently listed in the Orange Book.  Are the three new patents a game-changer?

Read More
Markman AdvisorsCorcept, Corcept Therapeutics, Teva, CORT, TEVA, Orange Book, Cushing's, Cushing's disease, Cushing's syndrome, mifepristone, Korlym, Inter Partes Review, IPR, patent misuse, generic, pharmaceutical, Hatch-Waxman Comment
Did Corcept and Teva tell the Court they are about to settle the Korlym patent dispute?

On January 10, counsel for Corcept ($CORT) filed a letter with the Court in the pending patent litigation against Teva ($TEVA) over its proposed generic for Korlym®.  (See Dkt. 49).  Within that letter, Corcept requested an extension of one week to respond to Teva’s Answer to the Amended Complaint.  Corcept’s letter further stated that the “parties are currently discussing a potential agreement that would eliminate the need for Corcept to respond to Teva’s Answer . . . .”  Is that potential “agreement” a resolution to the litigation?

Read More
Markman AdvisorsCorcept Therapeutics, Corcept, CORT, Teva, TEVA, Korlym, Hatch-Waxman, patent, affirmative defense, patent misuse, Zachary Silbersher, SilbersherComment